

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number
WO 02/39120 A1

(51) International Patent Classification⁷: G01N 33/68

(21) International Application Number: PCT/US01/46753

(22) International Filing Date:
8 November 2001 (08.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/247,312 9 November 2000 (09.11.2000) US

(71) Applicant (for all designated States except US):
BIONOVA PHARMACEUTICALS, INC. [US/US];
353 East 78th Street, 20A, New York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GEORGE, Shaji, T.
[US/US]; 719 Carmans Road, New York, NY 11762 (US).

BURIONI, Roberto [IT/IT]; Via Vento 50, I-61033 Fer-
mignano (IT).


(74) Agents: MAHONEY, Joseph, A. et al.; Mayer, Brown &
Platt, P.O. Box 2828, Chicago, IL 60690-2828 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

[Continued on next page]

(54) Title: A METHOD FOR IDENTIFYING THE PROTEOME OF CELLS USING AN ANTIBODY LIBRARY MICROARRAY



(57) Abstract: The invention describes a method for identifying the level of various proteins in a cells or tissue and also comparing the levels of the same protein in two different tissues which we have termed as Antibody Microarray Proteomics Technology (AMP Technology). Proteins that are differentially expressed between a normal and disease tissue could be involved in the disease process and hereby makes it a portential drug or diagnostic target. AMP technology makes use of the method of phage display selection or similar combinatorial antibody selection techniques to select antibodies to a given protein. Antibodies to all of most proteins present in the diseased and normal tissue are produced in an appropriate animal (mice) and mRNA encoding antibodies are isolated, cloned into filamentous phage (or bacteria or yeast) vectors such that the antibodies are expressed as a fusion with the phage filaments. Phage clones that express antibodies to different proteins in a tissue are microarrayed on a glass slide coated with polystyrene using an automated array spotter. Proteins from both the disease and normal tissues are extracted, conjugated with a flourescent label and incubated on two separete but identical arrays. Once the proteins are bounded to the antibodies on the array, they are washed and scanned using a flourescent scanner, which will quantitatively determine the level of each protein present in the cell.



CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

1 **A METHOD FOR IDENTIFYING THE PROTEOME OF CELLS USING**
5 **AN ANTIBODY LIBRARY MICROARRAY**

5 **RELATED CASES**

10 This application claims priority to U.S. Patent Application Serial Number 60/247,312
10 filed on 9 November, 2000, which is incorporated herein by reference in its entirety.

15 **FIELD OF THE INVENTION**

15 The present invention is related to a method for using phage display immunoselection
20 or similar techniques in order to use combinatorially selected antibody or antibody fragments
20 against cellular proteins so as to allow one to quantitatively and qualitatively determine the
25 level of known and unknown proteins in a cell or tissue by arraying a sufficiently large
25 number of such antibodies to allow maximum representation of antibodies against the cellular
30 proteins and capturing the cellular proteins from the cells or tissues of interest. The method
30 allows one to compare the levels of a known or unknown protein between a normal and a
35 disease tissue or a cell as well as allow to determine the level of various known and unknown
35 proteins in a cell or tissue.

40 **BACKGROUND**

40 Proteomics is the study of the proteome (all the proteins produced from all the genes
45 of a genome). Proteomics is an emerging field in biomedical research and is believed by
45 many to become the new century's superhighway to biomedical knowledge. Proteins carry
50 out most functions of the human body. When levels of certain crucial proteins are altered or
50 when they are mutated or when their interaction with other proteins is disrupted, it often leads
55 to disease. Understanding such changes in protein levels and function is crucial for proper
55 understanding of the disease process, which in turn will spur the development of a host of
new drugs and diagnostics to effectively manage these diseases. Proteomics deals with
understanding the role of proteins in health and disease. Already a dramatic shift in the

1 emphasis from DNA and mRNA (which codes for proteins) sequencing (exemplified by the
several genomic companies) to the study of proteins involved in diseases is becoming
5 evident. It is dawning on government-funded laboratories and drug companies that mass
sequencing of genomic DNA and spotting cDNA onto chips may not lead to the promised
10 land.

Limitations of genome-based drug target identification techniques:

15 The genomic revolution will undoubtedly generate massive amount of important
information on the genes. However, a far greater challenge is to determine the function of
20 each of these genes and their role in the etiology and progression of human diseases. Only
through such knowledge can the vast amount of genomic information gathered can be put to
25 practical use. Much of the deciphering of the genomic information will come from the
understanding of the function of the proteins encoded by these genes and the field of
30 proteomics will play a very major role in this process.

The genomic technologies despite their high profile, have major shortcomings.

35 They do not take into account:

- pre-translational events (mRNAs coding for various proteins being cut and spliced to
40 which leads to their translation into variants such proteins with different functions),
- translational efficiency (the number of protein molecules that can be made from one copy
45 mRNA, which varies widely from mRNA to mRNA) and
- Post-translational modifications (most often it is not the level of proteins, but
50 modifications like phosphorylation that modulate the function of proteins).
- There are no drugs that are mRNAs and there are only a handful of drug targets that are
55 mRNAs, but proteins are and it is essential to understand the role of proteins in diseases
to develop new drugs and diagnostics.

1 Knowledge about the role of various proteins in diseases (like the role of NEM in
prostate cancer) will be invaluable to major drug and diagnostic companies and they are
5 investing heavily for obtaining the commercial rights to develop products based on such
targets. Most experts in the field believe that unraveling the complex proteome of the cell will
10 revolutionize the biomedical field and lead to the discovery of a new generation of drugs and
diagnostics.

15 Current techniques of proteome analysis and their limitations:

Proteomics technology is still in the process of being defined. Currently there are a
20 dozen companies and several academic institutions involved in proteomic research.

A promising technology that is being developed by Phylos (Cambridge, MA) uses a
25 new technology called, mRNA display, which uses covalent fusion between an mRNA
present in a cell and the protein encoded by such mRNA. The complex can then be separated
30 on a DNA chip. The technique relies on isolating mRNA from tissues in the state in which is
present in a functioning cell followed translating it in-vitro without any alteration in the level
35 of mRNA due to degradation, a tall order due to the rapid breakdown of mRNA in cell
extracts. Even if this hurdle can be overcome, the translational efficiency of mRNA within a
40 cell may be significantly different from an in-vitro system, thus skewing the results. The
technology has several other technical hurdles to overcome. Another company called
45 Ciperagen (San Diego, CA) manufactures small chips, which is coated with media that can
separate proteins. Separated proteins can then be analyzed by MALDI-TOF. However, it is
50 difficult to isolate proteins from such media for further characterization. Other companies
like DYAX and Cambridge Antibody Technology are attempting to generate antibodies
55 against proteins that are identified by the genome sequencing effort (currently protein
sequence encoded by 30,000 of the more than 100000 genes are known) and using such

1 antibodies to separate proteins. These technologies don't take into account many of the
modifications that are crucial in determining the role of proteins in diseases.

5 To achieve the oft-stated goal of proteomic analysis requires that one be able to
separate all the proteins present in the cell, identify them, and analyze the state of their post-
10 translational modifications. "Global proteomics" of this sort is often likened to the use of
array technology to scan genes for mutations or to sample mRNA population of a cell. It is
15 important to note that this is a facile comparison and proteomics is considerably more
complicated than functional genomics. The latter techniques do not require separation of the
20 mRNA population into its individual components. However, one must keep in mind that
because of alternate splicing and post-translational modifications, there are far more protein
25 moieties in the cell than there are genes. Thus, true global proteomics may require techniques
that can resolve as many (or more than) twenty thousand proteins – certainly at least ten
30 thousand – from any given cell or tissue type and identify these proteins successfully in the
face of a likely 100,000-fold variation in levels of abundance.

35 Currently, in academic and industrial settings, centers for proteomics almost
invariably follow the same model: use of a two-dimensional (2D) gel electrophoretic analysis
40 to separate proteins and protein mass fingerprinting by mass spectrometry or chemical
sequencing of peptide fragments in order to identify the proteins present in the spots on the
45 gels.

The main limitation of this technique is that the gels rarely resolve more than 1000-
50 2500 proteins present in a cell while there are 15000-20000 or more different protein species
present in any given cell. Furthermore the major proteins present in a cell that have less role
55 in disease process (structural proteins) tend to mask the less-abundant proteins that have far
more crucial role in diseases. Despite the fact that even the best protein microchemistry
facilities can identify, under the most favorable circumstances, perhaps 10-20 proteins a day,

1 the marriage of these techniques has often been termed as "high throughput proteomics". It is
indeed very difficult to automate the 2D-gel technique and it is inherently a slow process.

5 In order to identify proteins involved in disease, the proteins from normal and disease
tissue are extracted and separated on 2D gels, stained with a suitable dye and visualized.
10 Proteins whose abundance varies significantly between the normal and disease tissue are
targeted for further study. The protein spots are manually cut out from the gel (a slow and
15 tedious process), the proteins eluted from the gel, and the identity of these proteins
determined by peptide fingerprinting using MALDI-TOF (Matrix Assisted Laser Desorption
20 Time of Flight) mass spectrometry or by chemical sequencing. Attempts at using MALDI-
TOF spectrometry to determine the sequence without eluting the proteins from the gel are
25 underway, but not yet perfected.

Requirements for true high throughput proteomics:

30 Reaching the stated goal of high throughput "global" proteomics will therefore
demand significant new technologies for:

- 35 • efficient and rapid separation of all proteins present in a cell or tissue
- identification of even minor proteins present in a cell, which may be 100,000-fold less
40 than the most abundant protein
- techniques to identify the separated proteins in the separation media or techniques that
45 can rapidly identify the proteins outside the media
- automation of the process

50 SUMMARY OF THE INVENTION

Disclosed is a method and composition for the study of the proteome of a cell or
55 tissue. The invention called high-throughput "Antibody Microarray Proteomic Technology"
(AMP technology) would overcome many of the inherent deficiencies associated with the
current proteomics methods. The key to the technology is the ability to rapidly develop a

1 library of monoclonal antibodies directed against most of the proteins present in a c ll. The
antibodies are then arrayed on a microarray slide and the various proteins present in disease
5 and normal tissues are rapidly separated on the microarray. Proteins whose levels are
significantly altered or proteins that are modified in a disease tissue could be potential drug
10 targets. The partial sequence of these proteins can then be easily determined using currently
available mass spectrometric techniques (MALDI-TOF) and automated chemical sequencing.
15 Such proteins can be further purified in larger quantities relatively easily using the same
antibody. Proteins of interest are further analyzed in detail for their role in disease process.
20 The technology would be significant improvement over currently used proteomic techniques
for the identification of potential protein drug targets. Furthermore, the same antibody that
25 was used for the identification of the potential target can be used for further validation of the
target in cell culture and animal models thereby expediting the process of drug discovery and
30 saving time and resources. Even intracellular proteins can be studied by cloning the cDNA
encoding the antibody into each cell to produce specific knockouts, a tremendous advantage
35 over other techniques. The key aspects of this proprietary technology are outlined in figure

Specifically disclosed are methods for production of antibodies against most proteins
40 including many proteins present in smaller amount antibodies in animals, preventing the
dominance of certain major epitopes over minor ones. The invention further discloses
45 displaying the antibody fragments on a filamentous phage followed by selecting the phage
expressing the antibodies against the proteins and arraying phage clones displaying individual
50 antibodies against each protein on a glass slide and using such microarray to capture proteins
in a cell or tissue that are prelabeled with a detection tag like flourescein and monitoring the
55 level of binding of the protein to each antibody on the array using a fluorescent scanner. In
the preferred embodiment, one would array a very large number of antibodies or phage

1 displaying antibodies on the slide (usually exceeding 0.5 million) in such a way that there is
maximal representation on the array of the various antibodies against different proteins.

5 Also disclosed is the use of such antibody microarrays to determine the level of
various known and unknown proteins that are present in diseased and normal cells. By using
10 identical arrays to capture proteins present in a disease and normal tissue, one can determine
the level of each protein that is present in each of the tissue by determining the amount of
15 fluorescent-labeled protein bound to the antibody. Identification of the levels of each protein
would allow one to determine the potential role of each protein in the disease process. Such
20 proteins could be potential targets for therapeutic intervention or could potentially be used as
markers for diagnosis of diseases.

25 Proteins of interest (proteins that are differentially expressed between disease and
normal tissue) are purified in larger amount by immunoaffinity chromatography using the
30 same antibody

The invention has several advantages over some of the current technology, which uses
35 two-dimensional gel electrophoresis as described below.

- the technology allows rapid (high throughput) analysis of thousands of proteins present in
40 a tissue simultaneously
- The arraying and screening can be automated, allowing thousands of samples to be
45 analyzed each day
- Antibodies against proteins present in a tissue are produced simultaneously using
50 techniques developed in our laboratory
- Unlike 2-D gel separation techniques (which allows separation of only 5-10% of the
55 proteins in a tissue), AMP technology allows the separation of almost all the proteins
present in a tissue
- No messy cutting out gel pieces or elution from gel, a tedious and inefficient process

- 1 • 2-D gel based proteomic techniques require the fragmentation of proteins prior to their
elution from gel. Hence using 2-D gel techniques one cannot usually obtain intact
5 proteins, but only fragments but AMP technology allows the isolation of full-length
proteins enabling more precise characterization of the protein.
- 10 • The technique should allow the detection of even proteins that are expressed in very small
amounts
- 15 • The technique allows the detection of even many proteins that are post-translationally
modified, particularly when they are phosphorylated or sulfated, key modifications that
20 alter protein function
- The same antibody in the array that was used for the capture of the protein can be used for
25 immediate larger scale purification of the protein by antibody affinity chromatography for
further characterization.
- 30 • Another very important feature of AMP technology is that once a differentially-expressed
protein target has been identified, the same monoclonal antibody that was used in for
35 identification (and isolation) of the protein target can be used for further easy validation
of many target proteins (similar to how NEM antibody was used to identify the role of
40 NEM in cancer)
- If the target were intracellular, then the cDNA encoding the antibody, which can be easily
45 isolated from the phage using simple PCR techniques, would be cloned into immortalized
cells from the disease tissue. The intracellularly-expressed antibodies can be used as
50 molecular knockouts of target proteins thereby helping to further understand the role of
these proteins in the disease process. This will considerably accelerate down stream target
55 validation, a major advantage over contemporary methods.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 describes a schematic of the entire process of Antibody Microarray Proteomics Technology

DETAILED DESCRIPTION OF THE INVENTION

A method of, and composition for, generating antibodies against many or all proteins present in a cell using combinatorial antibody selection in mice or other animals is described.

Also described is the use of such a library of antibodies arrayed on a microarray slide and use of such microarray to separate fluorescent-tagged proteins that are present in a cell. The fluorescent-tagged proteins are then captured by the antibodies on the microarray and quantitated by measuring the level of fluorescence bound to each spot on the array using a fluorescent scanner.

Extraction of proteins from cells:

A variety of published methods are available for extracting intact proteins from biological materials like cells, tissues or pathogens like bacteria or fungi or plant materials. If the biological material is mammalian cells, the cells are generally disrupted using a Dounce homogenizer or a Potter-Elvehjem motor driven homogenizer in a buffer containing isotonic salt solution at near neutral pH and detergents like Chaps, Triton X-100, NP 40 or other detergents which are usually non-ionic, but may be anionic or cationic. Generally such extraction buffers should contain protease inhibitors like phenyl methyl sulfonyl fluoride or peptides like leupeptin or aprotinin. Furthermore, the biological material should be as fresh as possible or should be freshly frozen to prevent degradation of proteins. If one does not intend to extract membrane proteins, it is not necessary to use detergents. After the extraction, the debris is separated by centrifugation and the supernatant is used for further steps. If there is a layer of fat (as with liver tissues) that is also removed. Another agent that dissolved proteins effectively is 0.1 N NaOH, which can be neutralized easily with an acid like trichloroacetic

1 acid or dichloroacetic or Tris base acid after extraction. This will obviate the need to use
detergents. Often it is advisable to remove the detergents before they are used to prevent
5 micelles trapping multiple proteins within them. For example, one could precipitate the
extracted proteins with trichloroacetic acid, washed several times with the same acid, and
10 the precipitate washed with the same acid and then dissolved in 0.1 N NaOH and the solution
neutralized with a buffer like Tris base. Alternatively certain commercially available organic
15 solvents can be used to remove detergents. However, one has to be careful to add back any
small peptides that are not precipitated with acid. Several other diverse methods have been
20 used to extract proteins and the above methods are only some commonly used examples.
Often disruption with an ultrasonic sound (sonicator) also helps to break up the membranes
and other organelles and release proteins. This method increases the efficiency of
25 solubilization by detergents or other agents.

30 Even in the absence of detergents some proteins tend to bind or stick to one another
proteins through Van Der Waals forces or hydrogen bonds or ionic bonds or other types of
35 hydrophobic or hydrophobic or hydrophilic interactions. Many hydrophobic interactions can
be disrupted by mild chaotropic agents like KSCN while hydrophilic or ionic interactions can
often be disrupted by salt. Covalent disulfide bonds can be broken by treatment with beta-
40 mercaptoethanol.

45 However, if one needs to achieve complete separation of proteins, one can treat the
protein mixture with a mild protease like stromolysin, chymotrypsin, cathepsin D etc. This
will release hydrophilic peptides, which does not stick to each other in mild salt solutions
50 (0.15 M NaCl). The hydrophobic peptides that may clump (only some peptides will tend to
clump) can be removed by centrifugation or hydrophobic chromatography on a C-3 or C-4
55 column or phenyl Sepharose chromatography or sometimes even by ultracentrifugation.

1 Subjecting complexes to ultrasonic sound (sonicator) also helps to break up potential
aggregates.

5 Source of proteins may include human tissues or cells, other animal tissues, pathogens
like bacteria, fungi, parasites like malarial parasite, or plants depending on the proteome one
10 wants to study.

Immunization of host:

15 Different types of animals can be used for immunization with the proteins. Although
the preferred animal is the Balb C mouse, other animals like rabbits, rat, or larger animals can
20 be used. Prior to immunizing the animals, the biological material is homogenized very finely
with either a Polytron homogenizer or a motor driven homogenizer in buffer or mild
25 solubilizing agents that are not toxic to the animals. The extract can be directly injected into
the animals without further separation.

30 However, in order to obtain the best results, one should remove the major structural
proteins that are present in the cell like histones, ribosomal proteins, albumin, certain
35 cytoskeletal proteins etc. Such proteins make up more than 90% of the protein mass of the
cells. They can be easily removed by immunoaffinity chromatography using a mixed
40 immunoaffinity resin. Such an immunoaffinity resin will have antibodies against the
structural proteins coupled to it. The protein mixture prior to immunization can be removed
45 by binding them to the antibodies immobilized on the resin. The protein that does not bind to
the resin (non-structural proteins) can be then used for immunization of mice. Several
50 methods of immobilizing antibodies to various matrices like Sepharose, Sephacryl etc., have
been described by many authors. Antibodies to most major structural proteins are
55 commercially available.

To further improve the chances of generating antibody against even minor proteins,
one should extract the proteins using one of the methods described above. It is not always

1 | necessary to completely break up aggregates since they will be proteolytically degraded by
the mouse.

5 | Prior to immunization, it is useful, but not always necessary to separate the proteins
into multiple fractions (5-50). Each fraction can then be injected into a separate mouse. This
10 | will allow one to decrease the number of diverse proteins that are injected into each animal
and will increase the chance that there is adequate representation of even minor proteins in
15 | sufficient amounts injected into each animal. This also will allow larger amount of such
minor or poorly antigenic proteins to be injected into each animal. The fractionation of the
20 | extracted proteins into various fractions can be performed using chromatographic techniques.
These techniques include, but are not limited to ion exchange chromatography on an anion or
25 | cation exchange resin, gel filtration, electrophoresis, electrofocussing, hydrophobic
chromatography or other protein separation techniques. Several methods of separating
30 | proteins into fractions are published. The separated proteins are collected in fractions and
each fraction is separately injected into different animals.

35 | Preferred routes of injection include injection into the popoteal lymph nodes or
subcutaneous injection. It is necessary to use an adjuvant like RIBI immunogen or similar
40 | products to enhance the immune response. Booster doses of the protein are injected after one
and two-week interval and the animals sacrificed after 30 days or more, the spleen of the
45 | animals are removed, and mRNA extracted as described above. If the protein mixture were
injected in multiple mice, then the mRNA fractions are pooled before further processing. The
50 | variable chain of the antibody chains (V_H and L_H) encoding the immunoglobulins is amplified
using IgG specific primers using PCR techniques. The PCR amplified fragments are cloned
55 | into the phage vector using standard recombinant DNA techniques.

1 Alternatively, one could immunize mouse or other transgenic animals that carry genes
that express human antibodies. This will generate human antibodies, the cDNA of which can
5 then be cloned into appropriate vectors.

Cloning of antibody cDNA into vector:

10 One can follow several methods for cloning the antibody cDNA into various vectors.
A common method of displaying antibodies is by cloning the cDNA encoding the antibodies
15 into the gene encoding the filament of filamentous phages (Mc Cafferty et al 1990; Barbas,
et al , 1991). In general antibodies or the fragments of antibodies (variable regions) have been
20 fused to the N-terminus of the minor coat protein pIII of the phage or to the C-terminal
domain of pIII and displayed as Fab fragments (Hoogerboom, et al, 1991) or as single chain
25 Fv (scFv) fragments (Mc Cafferty, et al, 1990) in which the CH and VL domains are linked
by a flexible polypeptide (Bird et al., 1988; Huston et al, 1988). With Fab fragments, one
30 chain is fused to the phage and the other secreted into the cytoplasm. Alternate hosts like
bacteria or other unicellular organisms can also be used for displaying antibody or fragments
35 of antibody. Protease sensitive sites can be engineered at both termini of the antibody or
fused V_H and L_H fragments so that they can be released as functional antigen binding
40 sequences by treating with the appropriate proteases, which can then be separated, from the
phage or bacterial host.

45 For cloning the antibody fragments in the appropriate vector, the total mRNA from
the spleen or other source of lymphocytes or spleen of the immunized animal (or human bone
50 marrow) is extracted taking care to prevent degradation using standard methods of mRNA
isolation. Repertoires of antibody fragments are first generated by PCR from rearranged V
55 genes (Orlandi et al., 1989; Ward et al, 1989; Husc et al, 1989; Clackson et al 1991). Once
could also use the peripheral blood lymphocytes or bone marrow (preferred) from humans, if
one intends to generate an antibody array of antibodies isolated from humans (Williamson et

1 al, 1993; Burioni et al, 1994). The latter technique is particularly useful for studying
autoimmunity as well as pathogenic infection in human subjects.

5 A variety of vectors can be used for expressing antibodies on phage filaments. These
include phage vectors, which encode the pIII fusion and all functions required for replication,
10 packaging, and infection of bacteria, phagemid vectors, which require rescue with a helper
phage. The latter vectors comprise the pIII fusion, plasmid, and phage origins of replication
15 and antibiotic resistance markers. Other vectors, fusing the antibody to other phage proteins,
as protein VIII, more represented in the phage structure, could also be used for a full
20 exploitation of the procedure. The helper phage provides the other functions for single-
stranded replication and packaging. Helper phages are very poorly packaged in competition
25 with phagemids due to defective origin.

Amplification of library:

30 The bacterial strains TG1[K12, D(lac-pro), supE, thi, hsdD5/F' traD36, proA+B+,
lacI, lacZDM15] are typically used for propagation of phage particles and HB21521
35 nonsuppressor strain (K12, ara, D(lac-pro), thi/F' proA+B+, lac^qZDM15) for expression of
antibody fragments. If a phagemid is used for cloning the antibody fragments, a helper phage
40 like VCS M13 (Stratagene) and M13 K07 (Pharmacia) can be used to rescue the phage
displaying the antibody fragments as described by the manufacturer.

45 The phage library in the appropriate bacterial host is grown and harvested in log phase
(0.6 OD). The phage particles are isolated by standard methods (Harrison, et al 1983).

50 The antibody cDNA that are represented in the library at this point will have all the
antibodies expressed by the host and not merely the antibody to the antigens that were
55 injected. Furthermore, the majority of combination of heavy and light chains will not
generate fully functional Fabs. Hence the phage expressing the antibody to the injected
targeted antigens are selected by panning against the same proteins that were injected. The

1 antigens are usually immobilized on a polystyrene or similar support. The stringency of
selection can be increased by reducing the density of coating of the antigen to the solid
5 surfaces or by increasing the time of washing or the concentration of detergents. To avoid
nonspecific binding of phage to the polystyrene or other surface, milk proteins or other
10 commercially available blocking agents are used. Usually the proteins are suspended in PBS
containing low concentration of detergent (0.1% Tween 20 or NP 40). The antigens that are
15 immobilized are the same as that the ones that were injected into the host. Immobilization is
usually achieved by overnight incubation of the antigens with the support (immunotube)
20 overnight and unbound proteins removed by washing with PBS.

The phage particles (10^{12} - 10^{13} t.u) are bound to the immobilized protein in the
25 immunotube, by incubating them in the immunotube for 30 minutes and washed a few times
with PBS containing 0.1% Tween and with PBS alone and the phage the bound phage is
30 eluted usually with 100 mM triethylamine and immediately neutralized with Tris-HCl pH 7.4.

The eluted phage is used directly for plating on agar plates. However, if the too many
35 phage particles expressing irrelevant antibody fragments or no antibody fragments at all are
present, one or two more cycles of panning are performed. This is done by infecting bacteria
40 with the eluted phage, amplifying the library and (after helper phage infection) the phage
harvested. The harvested phage is again panned against the immunotube with the bound
45 antigens, washed and the bound phage eluted. More than three cycles of panning is not
advised since it reduces the representation of antibodies that are present in the library.

50 One major difference of the present technique from routine techniques that are used
for isolating antibodies displayed on phage or bacteria is that fewer cycles of selection are
55 employed. Generally they are limited to one or two cycles. This increases the representation
of the antibodies against minor proteins or poorly antigenic proteins.

1 | Competitive deselection of immunodominant epitopes:

5 This technique is critical for the increased representation of antibodies against less
represented antigenic determinants. It also increases the efficiency of antibodies of rare
specificities. The inclusion of the technique allows far fewer antibodies to be arrayed on the
10 microarray to represent antibodies against most of the antigens. The protocol is a
modification of a standard panning protocol, except that the phage library is first preabsorbed
15 on the antigen of interest to remove phage that react with the immunodominant epitope. The
unbound phage are then incubated a second time with the antigen, and then eluted and
20 amplified as per normal protocols. However, the subtraction of unwanted clones is only
partial, and should be considered as "negative enrichment" rather than a complete
25 subtraction. Although subtracted clones are usually present at the end of the panning
procedure, their frequency is considerably lower and that obtained with an unmodified
30 panning procedure. This allows for the representation of rare clones and does not affect the
success of the technique. The same technique can also be used if the vector is a bacterium.

35 | Isolation of phage clones:

The phage library is used to infect a bacterial lawn such as to produce well-separated
40 phage plaques (Sambrook et al, 1991) after helper phage infection. Generally 100 or more of
150-mm plates are necessary to generate a library of phage that would display antibodies
45 against most of the antigens injected. If the antibody is displayed on a bacterial host having
an antibiotic resistance gene, the bacteria is plated on an antibiotic plate and the colonies
50 harvested.

The phage clones are either harvested manually using toothpicks or using an
55 automated plaque picker (like GeneTAC G³ from Genomic Solutions, Cambridge, MA). The
plaques are used to infect bacterial host that are plated in multiwell plates and amplified.
Aliquots of the phage are harvested, and used for arraying on glass or plastic microarrays. If

1 the antibody is displayed on bacterial host, the bacterial colonies are grown in multiwell
plates and aliquots are removed for arraying on microarrays.

5 Microarraying of phage or antibodies or Fab fragments:

The phage clones or bacterial clones displaying different antibodies arrayed on a
10 microarray slides similar to the microarray slides manufactured by Molecular
Dynamics/Amersham Pharmacia Biotech. The slides are coated with polystyrene or similar
15 materials that can bind proteins. Of particular use is the method used by Khrapko, et al (1996)
for immobilization of oligonucleotides, which can be modified for protein coupling, or
20 Versalinx (Prolinx, Bothell, WA, USA) slides. The former uses polyacrylamide pads for
coupling proteins. The N-terminal or lysine amino groups can be easily coupled to the protein
25 using carbodimide or after converting the amino groups into activated NHS ester.
Alternatively, one can also couple the phage through its SH groups to acrylamide that has
30 been modified to include SH groups. The Versalinx slides are pre-modified with
salicylthroxamic acid. The phage can be easily modified with phenyl boronic acid and a
35 complex between the phenylboronic acid and salicylthroxamic acid is formed to immobilize the
antibody on the glass slide. The technique is described by the manufacturer and is easy to use
40 for coupling phage through the lysine amino group or the sulfhydryl groups. Alternatively, the
slides are coated with resins that impart a positive charge to the slides, which are
45 commercially available. The phage or the bacteria can be arrayed directly on these slides
using an automated slide spotter (Amersham Pharmacia Biotech). Several such automated
50 slide spotters are commercially available.

Alternatively, the antibody can be excised from the phage or bacteria using
55 proteolytic enzymes like stromolysin. The phage vectors and bacterial vectors have
stromolysin or other protease sensitive sites built into the vector such that the antibody can be
released by the protease treatment. The released antibody can then be purified on mini-

1 protein A-Sepharose columns or antibody columns prior to arraying on the slides. The
antibody can then be bound to slides that are coated with protein A. The phage that is treated
5 with the protease is then arrayed on the Protein A slide and the remainder phage particles are
washed off with a PBS-Tween 20 (0.1%) buffer. Arraying the antibodies as opposed to the
10 phage or bacteria will reduce non-specific interaction with irrelevant proteins. Alternatively,
the antibody is excised from the phage and separately purified and arrayed on slides.

15 Yet another method for arraying antibody on glass slides is to coat the slides with
protein-A. Protein A binds IgG. The antibody displayed by the phage or bacteria are released
20 by appropriate proteases (depending on the protease site engineered into the vector) and the
mixture can then be directly spotted on the Protein-A coated slides. The antibody will
25 specifically bind to the protein A and the all the remaining phage or bacterial proteins can be
easily washed off with PBS-Tween. This method reduces the complexity of the operation.

30 Yet another way to immobilize the antibody is to engineer the cDNA that codes for 5-
6 histidine moieties contiguously with the amino terminal or the carboxy terminal of the
35 antibody or the Fab fragment. Stomolysin or similar protease sites are engineered on either
end of the antibody-histidine tag fusion protein for easy excision of the antibody such that the
40 antibody or Fab fragment will carry the histidine tag. The histidine residues can be utilized to
bind the antibody or Fab to slides that have nickel immobilized on its surface. Published
45 procedures for immobilizing nickel to glass slides or other supports are available.

Generally 10,000-50,000 separate phage or antibodies can be arrayed on one slide
50 without losing resolution during scanning. Higher densities of plating often reduce
resolution.

55 Replicates of the antibody arrays are made and used for screening. The microarrays
are stored at 4°C until further use.

1 Labeling of proteins:

5 In order to detect the binding of proteins to the antibody on the array a detection tag
needs to be used. The commonly used detection tags are fluorescent or radioactive tags.
CyDye, a fluorescent tag manufactured by Amersham Pharmacia is a good product for this
10 purpose. The tag as activated NHS-esters and readily reacts with the carboxyl end of proteins.
They also prevent cross-linking of proteins. Several other commercial dyes and activated
15 esters of these dyes are available. Another method is to radioiodinate the proteins in presence
of chloramine T.

20 Prevention of protein aggregation or non-specific protein-protein interactions:

It is important that the proteins remain as individual molecules and that they do not
25 clump together (except when functionally it exists as dimmers or multimers or are linked to
each other through disulfide bridges or exists are a multimeric protein unit as in the case of
30 RNA polymerase). Often many unrelated proteins clump together through either hydrophobic
or ionic interactions. This will cause multiple proteins to bind to the same antibody. We have
35 devised a novel method to overcome this problem.

If there is significant non-specific clumping of proteins, the proteins are first treated
40 with a protease that cleaves the protein infrequently like stromolysin or cathepsin D. This will
release large fragments of the protein, which still retain their antigenicity, but are freed of
45 protein-protein interactions. The aggregated fragments of the proteins are removed by either
filtration or ultracentrifugation or by size exclusion chromatography. The free fragments are
50 then labeled with the tag. Another efficient method of limited and specific cleavage of
proteins is by treating the mixture with CNBr.

55 If this particular path is chosen for the preparation of protein samples, then the same
protease-digested peptides must be used for panning selection of the phage to prevent
contamination by phage displaying antibodies that recognize only the full-length protein or

1 | protein fragments that have been removed. Generally the more hydrophilic fragments tend to
be free of protein-protein interactions and stay as free molecules.

5 | Screening:

In order to achieve better representation of antibodies against as many proteins as
10 | possible, it is necessary to use sufficient microarrays that represent at least 0.5-1 million
antibodies, Fab fragment or phage. The number of separate antibody or phage required could
15 | be as high as 10 million. It is certain that many antibodies will be represented multiple times
on the array panel, but it is far more important to have a better representation of antibodies
20 | against diverse proteins and their modified forms. At times, far higher number of antibodies
would be necessary to be used to get adequate representation.

25 | There are several uses for these microarrays.

1. Comparison of the level of individual proteins between a normal and a disease
30 | tissue: Antibody microarray can be used to identify proteins that are differentially expressed in
the normal and disease tissue. For this particular use, duplicate microarrays are used. One set
35 | of microarray will be incubated with labeled proteins from the normal tissue or cells and the
duplicate set with labeled proteins from the disease tissue or cells. Proteins that are
40 | differentially expressed between a normal and disease tissue may be targets for therapeutic
intervention or may be markers for the disease, but such inferences would require further
45 | validation of the targets.

2. Determination of the level of proteins from single tissue or cells: In this case only
50 | one set of microarray slide is used.

Overcoming antigen overload: Since the arrays are plated with the same amount of antibody
55 | at each position, it is conceivable that certain proteins that are present in high concentration in
the cell or tissue may overload the antibody and the results obtained would not be
representative. There are two solutions to this problem. Either one can increase the

1 concentration of antibody that is spotted. Alternatively, antibodies can be coated at increasing
concentration on separate slides so that saturation of any of the antibody can be easily
5 monitored. If any protein saturates the antibody, there will be increased binding of protein to
the antibody spotted at the higher concentration.

10 Protein binding and washing: The labeled proteins are incubated with the antibody in an
incubation chamber for 30 min. to 2 hours. The slides are then washed with PBS containing
15 0.1% Tween 20 or other detergents and then scanned using a scanner depending on the label
used. The entire process can be automated using an automated microarray washer similar to
20 the one manufactured by Amersham-Pharmacia.

Scanning: If a fluorescent label is used, the microarrays are scanned in a fluorescence
25 scanner. If the proteins are radiiodinated, a gamma ray scanner is used. The intensity of the
spots is compared using commercial software similar to the one manufactured by Amersham-
30 Pharmacia and compared.

Amplification of signal: The sensitivity of the signal can be amplified by using standard
35 amplification techniques. For example, the proteins can be biotinylated using a NHS-biotin
ester, slides washed, then incubated with streptavidin conjugated to multiple molecules of
40 horseradish peroxidase or alkaline phosphatase, washed, and the slides incubated with the
substrates for the respective enzymes. Alternatively, the proteins can be conjugated to
45 digoxigenin and the protein-digoxigenin conjugate detected using an anti-digoxigenin
antibody conjugated to alkaline phosphatase or horseradish peroxidase.

50 Identification of protein:

Identity of the proteins of interest can be determined by a variety of methods. In the
55 preferred embodiment, adequate amount of the proteins of interest is purified from the protein
extract from the tissue or cells. This can be accomplished by conjugating the antibody against
the protein of interest to a matrix like Sepharose by published methods to generate an

1 immunoaffinity column, the protein is purified by immunoaffinity chromatography, and the
identity of the purified protein is determined. Alternatively, the identity of the antigen
5 antibody conjugate that is fixed on the microarray itself could be conceivably determined.

Identity of the purified or antibody immobilized protein can be determined by a
10 variety of methods. The protein is digested with proteolytic enzymes and a molecular weight
fingerprint of the fragments can be identified by Matrix Assisted Laser Desorption
15 Ionization- Time of Flight (MALDI-TOF) spectrometry and compared with protein digest
patterns of proteins available with protein data banks like Swiss Prot. MALDI-TOF also
20 gives the sequence information of small peptide fragments. The sequence identity of the
peptide fragments after their separation by chromatography can be determined by
25 electrospray spectrometry and Edman automated sequencing.

Key steps of AMP technology:

- 30 1. Extract proteins from normal and disease tissue
2. Remove major structural proteins (like actin, histones) by affinity chromatography
- 35 3. Inject proteins into mice, boost several times
4. Extract lymphoid mRNA, reverse transcribe immunoglobulin heavy chain (V_H) and light
40 chain variable domain (V_L) repertoires
5. Display total V_H and L_H on M13 helper phage (or in bacteria or other hosts)
- 45 6. Subject phage to competitive deselection of dominant epitopes
7. Pan phage library 1-3 times (in certain instances more) on immobilized protein (or
50 peptide fragments) used for immunization in order to enrich phage-expressing antibody to
proteins present in target tissue (immunodominant epitope deselection).
- 55 8. Expand each phage plaque in microtiter plates using automated phage picker.
9. Array phage displaying different antibody microarrayed on glass or other chips using a
fully-automated spotter

- 1 10. Bind fluorescent-labeled or radiolabeled proteins extracted from diseased tissue and
normal tissue to antibody microarray chip. The proteins may have to be treated with
5 proteases to release large fragments and such fragments are separated by centrifugation
prior to labeling and binding to reduce non-specific binding to the array due to clumping
10 of proteins. The chips are washed using a fully-automated chip washing machine
11. Chip scanned using a fully-automated or manual scanner
15 12. Proteins that are differently expressed in diseased and normal tissue are identified using a
commercial software program.
20 13. Proteins of interest are re-selected on a larger scale using the specific monoclonal
antibody that recognizes the protein.
25 14. The peptide sequence fingerprinting of the protein performed using MALDI-TOF or
using automated peptide sequencing machine
30 15. The proteins are analyzed using various protein and gene database (bioinformatics)

SPECIFIC EXAMPLES

35 **Example 1: Removal of major structural and other proteins:**

The tissues or cells are solubilized using a variety of published techniques (Methods in
40 Enzymol., Vol, 31). In a nutshell, fresh tissue is removed and cut into small pieces (2 mm)
and washed with ice-cold PBS and then ground using a Dounce homogenizer or a Potter-
45 Elvehjem homogenizer or a Polytron homogenizer in presence of a detergent like 1% Triton
X-100 or 1% NP 40 or 2% CHAPS or other commonly used detergents. For solubilizing
50 cultured cells, a solubilizing agent called M-PER (Pierce Chemical Company, Rockford,
IL) or similar reagents are used. 25 volumes of ice-cold M-PER reagent containing protease
55 inhibitors were added and the cells were homogenized using a Dounce homogenizer (20
strokes). The homogenate is centrifuged at 100,000 g for 1 hour and the supernatant removed.

1 The solubilized proteins present in the supernatant were used for further steps. In certain
cases, the 0.25M sucrose was included (for brain tissue 0.32M).

5 When serum samples were used, no solubilization reagents or detergents were used.
The sample was used directly for the next step.

10 When only cytosolic proteins were used, the cells were lysed by either hypotonic
shock in conjunction with Dounce homogenization in phosphate buffer, pH 7.2, containing
15 10 mM NaCl. The cytosolic fraction was separated from the rest of the cell fractions by
centrifuging at 100,000 g for 1h and recovering the supernatant.

20 All solubilization or extraction buffers contained 0.1M PMSF, 0.2 mM EDTA and
0.8mM benzamidine and in some cases 10ug/ml of Leupeptin and/or aprotinin was also
25 included to prevent proteolytic degradation (if the latter were added, they have to removed by
immunoaffinity chromatography prior to immunization). The entire process was done
30 between 0-4°C. The extracted proteins are processed as immediately to prevent any
proteolytic degradation or snap-frozen for later use.

35 Preparation of immunoaffinity column: Immunoaffinity resins to remove major
structural and other major proteins were made as follows. Monoclonal or affinity-purified
40 polyclonal antibodies against the various major proteins are commercially available. The
antibodies are conjugated to NH-activated Sepharose (Amerhsam-Pharmacia) or similar
45 supports according to the methods prescribed by the manufacturer. The antibody
concentration was maintained at approximately 1 mg/ml of matrix (Sepharose), although this
50 was not very critical.

Several immunoaffinity matrix representing the various structural proteins were
55 mixed according to their approximate proportion in the cells to make a mixed bed resin.
Examples of proteins that are removed include histone proteins, ribosomal proteins,

1 polymerases, cytoskeletal components, albumin etc. The columns were equilibrated with
Tris-buffered saline.

5 The protein fraction was loaded onto these columns at a slow rate (one column
volume 20 min.) at 4°C and the fractions that did not bind to the protein were collected and
10 used for immunization. The same method was also applied to make protein fractions for
screening, if one was not interested in studying the structural proteins. When the profile of
15 expression of structural proteins also needed to be studied, then the antibodies against these
proteins were also included in the microarray.

20 Sometimes it is necessary to reduce the complexity (number of different proteins in
the sample) prior to injection into mice. This can be accomplished by different
25 chromatographic or electrophoretic methods or other commonly used methods of
fractionation. When the sample is constituted of digested peptide fragments, they are
30 separated into multiple fractions (5-50) on a C-3 or C-18 or similar reverse phase HPLC
column. Whole proteins are separated on an anion exchange chromatographic column
35 (Pharmacia Amersham FPLC column) or a size exclusion chromatographic column.
However, any of the several methods for fractionating proteins can be used alone or in
40 combination to separate the proteins into various fractions prior to injecting into mice, if the
antibody library efficiency is not adequate in the absence of such fractionation.

45 **Example 2. Blocking immunodominant epitopes by competitive deselection**

The protocol is a modification of a standard panning protocol, except that the phage
50 library is first preabsorbed on the antigen of interest to remove phage that react with the
immunodominant epitope. The unbound phage are then incubated a second time with
antigen, and eluted and amplified as per normal protocols.
55

1. Materials used

1. Antibody phage library freshly amplified according to standard protocols (see Note 1).

- 1 | 2. 0.1M carbonate buffer pH 8.6: for 1 liter, dissolve 8.4 g of NaHCO_3 in water, adjust pH
to 8.6, filter and store at 4°C.
- 5 | 3. PBS; PBS/0.5% Tween 20; PBS/1% bovine serum albumin (BSA); 2M Tris base.
4. Elution Buffer: per 200 ml, add 1.6 ml of 12M HCl to water, adjust to pH 2.2 with solid
10 | glycine. Autoclave and store at room temperature.
5. VCS M13 helper phage; *E.coli* strain XL1-Blue.
- 15 | 6. Tetracycline stock: 5mg/ml in ethanol; carbenicillin stock: 50 mg/ml in water; kanamycin
stock: 10mg/ml in water; store all antibiotic stocks at -20°C.
- 20 | 7. Superbroth medium (SB); SB with tetracycline (10 $\mu\text{g/ml}$ final concentration);
SB/carbenicillin (20 $\mu\text{g/ml}$ in low carbenicillin SB; 50 $\mu\text{g/ml}$ in high carbenicillin SB);
25 | LB agar/carb plates (100 $\mu\text{g/ml}$ carbenicillin).
8. PEG/NaCl:PEG-8000 20% w/v; NaCl 2.5M, autoclave and store at room temperature.
- 30 | 9. ELISA Plates (half area, high affinity binding: Costar Cat. No.3690); Oak Ridge
centrifuge tubes (Sigma, Saint Louis, Missouri) or immunotubes
- 35 | 2. Procedure
1. Coat ELISA plates or immunotubes with the appropriate amount of antigen in each well
40 | (see Note 2). Coat both the adsorption and panning plate at the same time. For the
adsorption plate coat at least 10 wells for each phage selection. For the first round of
45 | panning coat 4 wells; for the following rounds coat 2 wells per phage selection.
2. Incubate the sealed plate at 4°C overnight.
- 50 | 3. Wash both plates 5 times with distilled water (100 μl /well), then blot dry on paper towel.
Block both plates with 150 μl /well of PBS/1%BSA 2 hours at 37°C. Do not let the plates
55 | dry out (see Note 4).

- 1 4. At the same time inoculate a single fresh colony of *E.coli* XL1-Blue into 15 ml SB +
tetracycline in a 50 ml tube. Grow at 37°C in a rotatory shaker. Start the culture in time to
5 have bacteria ready for infection of step 9 (see Note 5).
- 5 5. Remove the block solution from the wells of the adsorption plate with a pipette and add
10 20 ul ($> 10^{10}$ cfu) of fresh library phage suspension to each of the ten wells. Phage is
resuspended as in step 16. Seal the plate and incubate at 37°C for 2 h.
- 15 6. Carefully and gently remove 15 ul of phage from each well of the adsorption plate and
combine in a 0.5 ml microfuge tube and keep on ice. Remove the blocking solution from
20 the panning plate and immediately add 50-70 ul of adsorbed phage to each well (25-35 μ l
in the first round of panning using 4 wells) Seal the plate and incubate for an additional 2
25 h at 37°C.
- 30 7. Wash the wells or tube 10X with PBS/0.5% Tween 20 (100 μ l/well), leave for 5 min then
discard washing solution. Use barrier tips to avoid contamination.
- 35 8. Elute the phages bearing specific antibodies by adding 50 ul of elution buffer per well or
1-5 ml for the immuotube depending on the size of the tube and incubating at room
temperature for 3 min. Remove the elution buffer into a microfuge tube and neutralize
40 immediately by adding 3 ul of 2M Tris per 50 ul of elution buffer for the ELISA plates
and 1 ml for immunotubes.
- 45 9. Add the eluted phage to 2 ml of exponential growth phase *E.coli* XL1 Blue (density
O.D.₆₀₀ = 0.6) and incubate in a rotatory shaker (230 rpm) for 15 min at 37°C.
- 50 10. Add 10 ml of prewarmed SB (low carbenicillin and tetracycline) to the 2 ml of infected
cells. Plate 10, 1 and 0.1 ul of the infected cell suspension on LB/carb plates and incubate
55 overnight at 37°C. Calculate the approximate number of eluted phages from the number
of colonies. Incubate the remaining cell suspension for 1 h at 37°C in a shaker.

- 1 11. Add 100 ml of pre-warmed SB (high carbenicillin and tetracycline) and incubate for 1 h
at 37°C in a shaker.
- 5 12. Add 10^{12} pfu of helper phage VCSM13. Incubate at 37°C in a shaker for a further 2 h.
- 10 13. Add kanamycin to a final concentration of 70 ug/ml, and incubate the culture overnight at
30°C in a shaker.
- 15 14. Centrifuge the cultures at 2,000g at room temperature in 50 ml tubes in a bench
centrifuge. Precipitate the phage from the resulting supernatant by adding 7 ml of PEG-
/NaCl solution to 30 ml of supernatant in Oak Ridge tubes. Incubate on ice for 30 min.
- 20 15. Centrifuge for 20' at 15,000g at 4°C and discard the supernatant. Let the tubes dry upside
down on paper towel for 2-4 min.
- 25 16. Carefully resuspend the phage pellet in 1 ml PBS/1%BSA per tube. Be careful to also
resuspend the pellet that usually forms on the wall of the tube. Transfer the suspension to
30 a microfuge tube.
- 35 17. Mix the tube by inverting several times (do not vortex). Centrifuge at 10,000g in a
microfuge at 4°C for 15 min then transfer the supernatant into a clean Eppendorf tube.
- 40 18. Use this phage suspension in subsequent rounds of panning (see Notes 6 and 7). It is
advisable to use four wells in the first round of panning and two for the following rounds..
Phage suspension from round showing enrichment can also be used to infect cells for the
45 production of soluble Fab (Burioni et al.1998).
- 50 3. Notes on procedure
- 55 1. The phage library or subsequently selected phage needs to be freshly amplified for each
panning cycle. Although phage molecules themselves are very stable and can be stored
for years at -70°C without losing infectivity, displayed antibody molecules on the surface
are not stable. Panning of a stored phage preparation can yield unpredictable results.

- 1 2. As a general rule dilute the antigen at a concentration 5 times greater than that used in
ELISA for detection of antibodies. If this ELISA concentration is not known use 500
5 ng/well of antigen for panning, and 100 ng/well for ELISA. This concentration is usually
suitable for the isolation of antibody-bearing phages. The volume in which the antigen is
10 added can range from 25 to 50 μ l. Optimal conditions for binding including temperature
of binding and coating buffer need to be determined experimentally for each individual
15 antigen. Most proteins bind well in PBS or in 0.1M carbonate buffer.
3. Check that the washing conditions used in panning do not detach bound antigen from the
20 surface of the plate. To exclude this possibility coat an ELISA plate with antigen, wash
using the same conditions used for panning, and then use the plate for an ELISA using a
25 antibody known to react with antigen.
4. Proper blocking of the wells is crucial. The procedure has to be performed simultaneously
30 for both the adsorption and panning plate. Do not let the wells dry out at any stage.
5. Infection of bacteria is a critical step. It is important that the optical density (OD) of the
35 *E.coli* culture is approximately that indicated (i.e. exponential growth) in order to obtain
maximal infection. Do not dilute the bacterial culture to obtain the correct OD but
40 schedule the time of inoculation of the culture appropriately.
6. Do not reuse the plates or immuotubes. Use a fresh plate for each round of panning, and a
45 different one for adsorption each time. The best results are obtained using plates freshly
coated with antigen.
- 50 7. It is a crucial point to obtain a suitable phage preparation for performing this procedure.
Low phage yield ($<10^{11}$ cfu/ml) usually does not allow a successful subtraction and
55 cloning. However it is obviously impossible to know the titer of a phage preparation at
the starting point, as it would take at least one day to determine it and the phage has to be

1 used freshly prepared. We usually rely on the evaluation of the growth of bacteria as seen
before centrifugation. A poor bacterial growth prompts for a restart.

5 8. Subtraction is not as efficient as selection. For this reason it is necessary to use ten wells
for absorption. In case of over-representation of clones this number can be doubled,
10 trying to keep to a minimum the total volume of phage. It should be noted that the first
panning round is crucial for successful selection. Number of wells can be increased as
15 well as incubation time. Some antigens require incubation at 4°C overnight, even if this is
rarely needed. In these cases subtract for 5 hours at 4°C using the same procedure. Do not
20 incubate more than overnight.

9. It is not advisable to perform more than 3 rounds of panning. After this point a dominant
25 (and often unwanted) clone will emerge.

Example 3. Proteolysis of target protein to prevent aggregation:

30 It is essential that any aggregates of target proteins or heteromeric protein-protein
interactions are disrupted prior to binding to the microarray. Such interactions are difficult to
35 break up hence we have devised a method to overcome the problem. Presence of proteins that
exist normally as dimmers or multimers or proteins that are functionally multimeric does not
40 pose a problem with the method. The target protein mixture is treated with a protease like
stromolysin or Cathepsin D, which has fewer proteolytic sites on proteins. Essentially, the
45 target proteins are incubated with 10 ug/ml of the protease and incubated at 20-37°C for 30
minutes in Tris-HCl or phosphate buffer (at the optimal pH of the protease) containing 150
50 mM NaCl (to break up potential ionic interactions) The proteases release large fragments of
the proteins. The hydrophobic portions of the proteins usually tend to aggregate in aqueous
55 media, while the hydrophilic pieces generally remain non-aggregated and free. Another
method for cleaving large proteins into fragments is through the use of CNBr according to
published methods. The aggregated proteins are removed by passing them through a size

1 | exclusion columns. The breakthrough fractions containing the aggregated proteins fragments
are discarded, while the dispersed hydrophilic molecules are eluted and concentrated prior to
5 | use. Alternatively the peptide fraction is separated from the aggregated protein fraction by
passing it through an Amicon ultrafiltration devise with a molecular weight cut-off of 10,000-
10 | 25,000 as described by the manufacturer. The ultrafiltrate is collected, concentrated by
passing it through an anion exchange column at pH 8.0 and eluted by lowering the pH or
15 | increasing the salt concentration. One could also use a variety of other published methods for
concentrating the peptides

20 | Alternatively, the digested proteins are centrifuged at 100,000 g for 2 hours to
sediment the aggregated fragments. The supernatant is collected and concentrated by methods
25 | mentioned above prior to conjugating with a detection label.

Example 4: Labeling of proteins and peptides:

30 | A variety of commercially available labeling reagents which includes fluorescent
dyes, radiolabel or chemiluminescent label can be used for labeling proteins. In the preferred
35 | embodiment, CyDye (Amersham Pharmacia Biotech, NJ, USA) is used as described by the
manufacturer. In a nutshell, the protein or peptide samples are incubated with the mono-
40 | reactive dye and the unreacted dye is removed. The dye reacts with the amino groups present
in the protein or peptide.

45 | **Example 5: Preparation of antibody microarrays:**

50 | Micro arraying of antibodies or Fab fragments are done as follows. Phage suspension
at an appropriate concentration are used to infect E.Coli as described above in the procedure
section. Infected cells are plated (after incubation) in LB/agar plates containing penicillin and
55 | tetracycline. Bacterial clones growing in ampicillin are containing the antibody genes bearing
phagemids. Bacterial colonies are picked using an automated picker and grown at 37°C in 96
well plates in SB (ampicillin-tetracycline). In the case of the use of antibodies for array

1 construction, infected bacteria are of the non suppressor strain and will produce soluble Fabs.
In this case after 5 hours of growth IPTG at a concentration of 1mM is added and cells are
5 cultured for further 15 hours at 30°C. The plates are spun down and the supernatant removed
using an automated liquid handling station. 50 ul aliquot of the supernatant (containing
10 depending on the procedure phage or free phagemid, that can be converted to phage upon
transformation and helper phage infection of host cells) is removed and stored at -20°C as
15 glycerol stock for future use after properly cataloguing it. If the antibody or Fab fragments
displayed on the surface of the phage has proteolytic cleavage sequences engineered on the
20 flanking regions, the phage is treated (if needed) with the proteolytic enzyme to release the Fab
fragment or the antibodies.

25 For antibody array construction the digest is passed over immunoaffinity column of
mouse anti-Fab antibody or single chain antibody coupled to Sepharcl. The columns are in
30 the same 96-well plate format for ease of use. Alternatively, Protein-A-Sepharcl column
can be used. The antibody or Fab fragment is eluted from the column and collected in tubes
35 in the 96-well plate format and stored in cold until arrayed on slides. The arraying performed
as soon as possible.

40 When the bacteria is used for displaying the Fab fragments or antibody, the same
procedure is used except that the colonies are grown overnight in LB in 96 well plates
45 (Quiagen), a portion of the bacteria removed and stored as glycerol stock at -90C and the
remaining bacteria spun down using centrifuge with a 96-well plate adapter, the pellet
50 washed two times in M8 salt solution and resuspended in the same solution and the Fab
fragments or the antibody excised with the proteases. After excision of the antibody, the
55 bacteria are spun down, the supernatant containing the antibody or Fab are removed and
purified as above and stored in 4C.

1 One could also spot the phage directly on the microarray. In this case, if the procedure
is intended to create phage microarrays, bacterial cells are grown for 1 hour at 37°C and after
5 this step 5 µl of a suspension of helper phage (containing $>10^{12}$ pfu/ml) are added to the
wells. After 2 hrs of incubation at 37°C kanamycin is added to a final concentration of
10 70µg/ml. Cells are grown for further 15 hrs at 30°C. In this case the supernatant is containing
phage.

15 Preparation of antibody microarray: Prior to spotting the antibodies, an analytical test
is performed to determine the efficiency of the antibody library. This step is done prior to the
20 harvesting of colonies described above. Typically sufficiently large number of phage clones
(between 0.5-10 million) is suspended in PBS/BSA1% and panned against very low
25 abundance proteins or peptides. Presence of protein-specific clones is then determined by
conventional methods. These proteins and peptides are chosen based on their level of
30 expression in the particular tissue or cell that is used. Alternatively, one could spike the
immunization mixture used for immunizing the mouse with protein from a different source at
35 a very low concentration (e.g. 1 part in 200,000 or 1 part in million) and screened for the
presence of antibody against this protein.

40 Alternatively the screening is done by transferring the phage to nylon membranes and
screening for the presence of the antibody using the respective antigens that are conjugated to
45 horseradish peroxidase or alkaline phosphatase (Maniatis, 1991). The efficiency of the
library is represented by the number of positive plaques in one million phage or bacterial
50 clones. When microarraying, care is taken to make sure that sufficient number of phage or
bacteria are chosen that these low abundant proteins are represented 2-4 times in the library.

55 Once the efficiency of the library has been determined and the number of antibody,
Fab, phage to be microarrayed has been determined, the samples are processed as described
above and they are microarrayed on an appropriate glass slide coated with a medium that binds

1 proteins efficiently like polystyrene. It is more efficient to use slides that are coated with
agents that form strong bonds with proteins. In the preferred embodiment, Versalinx slides
5 (Prolinx, Bothell, WA) are used. Versalinx glass slides are coated with pheylyboronic acid
and all non-specific protein binding sites are preblocked (an additional blocking with 0.1%
10 BSA can be done after arraying, if needed). The antibody or Fab or phage is treated with
salicylhydroxamic acid (as described by the manufacturer) and then spotted on the slides. The
15 salicylhydroxamic acid moieties on the antibody specifically bind to the pheylyboronic acid
moiety thereby immobilizing the antibody. One could use any technique that immobilizes
20 proteins on slides for the purpose of arraying.

Arraying of antibodies is performed using an automated microarray spotter similar to
25 the one manufactured by Pharmacia Amersham, (Piscataway, NJ). Replicates of the slides are
made and stored at 4C until use. Usually 0.5-10 million antibody, Fab or phage particles are
30 spotted depending on the efficiency of the antibody library as well as the abundance of the
proteins of interest in the library. Alternatively, the slide can be coated with anti-phage or
35 anti-Fab antibodies, or with proteins able to bind to the light chain of the Fab.

The fluorescent-tagged peptide fragments or protein from disease and normal tissue
40 are incubated in separate identical slides in PBS buffer and incubated for 1-10 hours. The
binding is done in an automated slide processor (Pharmacia Amersham) or similar
45 equipment. The slides are washed with PBS buffer, slides removed and scanned using a
fluorescence scanner (Pharmacia Amersham) or similar and the fluorescence acquired and
50 analyzed using a Gen3DB software (Pharmacia Amersham) or similar software. Identical
spots in duplicate slides which has significant difference in binding of the protein or peptide
55 as determined by the difference in intensity of the fluorescence are potential protein targets of
interest and are further evaluated.

CLAIMS

What is Claimed is:

1. A method for determining the level of known and unknown proteins in a tissue or cell, comprising: extracting the proteins from the target tissue or cell and using the proteins to generate an immune response in an appropriate animal host; cloning the antibody Fab fragment or the V_H and V_L chains or larger fragments of the antibody in phage such that the antibody is displayed on the surface; selecting the antibodies against the injected antigens by limited panning; isolating individual clones of phage; expanding the clones and spotting them on microarrays in sufficient number so that all or most the antibodies against the various proteins are represented in the microarray; allowing labeled protein from the target tissue or cell to bind to the antibodies on the microarray; and monitoring the level of the protein by scanning in a fluorescence reader machine, or a radioactive counter, or luminometer depending on the label.
2. The method of Claim 1 wherein the host is selected from the group consisting of:
 - a) a transgenic animal that carry human V genes or other human immunoglobulin components so as to produce largely human type antibodies; and
 - b) a mammal.
3. The method of Claim 1 for use to compare the level of expression of proteins between a diseased and normal tissue or cell.
4. The method of claim 1 wherein the antibody is selected from a library of phage expressing an antibody and displaying a random sequence representing the variable sequences by the method of in-vitro selection.
5. The method of Claim 1 wherein monoclonal antibody fragments against non-immunodominant antigenic determinants that are contained in the library phage display immunoselection have been obtained once the library of antibodies is first preabsorbed on


- 1 | the antigen of interest to remove antibody that react with the immunodominant epitopes
and the unbound phage is then panned again with the same antigen.
- 5 | 6. The method of claim 1 wherein monoclonal antibody fragments against non
immunodominant proteins are obtained from the library by panning against antigen(s) of
10 | interest after preabsorbing the library with immunodominant proteins contained in cells
lysate.
- 15 | 7. The method of claim 1 wherein monoclonal antibody specific for proteins of diseased
cells are obtained from the library by panning against diseased cells lysate after
20 | preabsorbing the library with proteins from healthy (related or unrelated) cells or with
similar cells lacking protein(s) when compared to the target cell.
- 25 | 8. The method of Claim 1 wherein the phage library bears antibody fragments from humans
infected with pathogens or have autoimmune disease.
- 30 | 9. The method of Claim 1 wherein proteins in abundance in cells, structural proteins and
immunodominant proteins are removed by the method of immunoaffinity
35 | chromatography.
- 40 | 10. The method of Claim 1 wherein the extracted proteins from target tissue or cells are
treated with proteases or CNBr so as to release fragments which do not aggregate or
interact with each other, the aggregated fragments removed by methods including, but not
45 | limited to size-exclusion chromatography, ion-exchange chromatography,
ultracentrifugation and the non-aggregated peptides are further used for screening
50 | microarrays.
- 55 | 11. The method of Claim 1 or 10 wherein the protein or peptides are conjugated to biotin,
incubation with streptavidin that is conjugated with horse radish peroxidase or alkaline
phosphatase or similar enzymes and detecting the presence of the peptide by incubation
with the respective substrates for the enzymes.

- 1 12. The method of Claim 1 or 8 wherein the protein or peptides are conjugated with
digoxigenin, incubation with an antibody against digoxigenin that is conjugated with
5 horse radish peroxidase or alkaline phosphatase or similar enzymes and detecting the
presence of the peptide by incubation with the respective substrates for the enzymes.
- 10 13. The method of Claim 1 wherein the vector is a phagemid, plasmid, lambda, filamentous
phage, bacteria, yeast or other unicellular organisms.
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55

Fig. 9.

AMP Technology

Normal and disease tissue



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/46753

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE, SCISEARCH, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | PLAISANT P ET AL: "Human monoclonal recombinant fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors." RESEARCH IN VIROLOGY, vol. 148, no. 2, 1997, pages 165-169, XP001062605 ISSN: 0923-2516 the whole document --- -/-- | 1-13 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

19 March 2002

Date of mailing of the international search report

08/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreno de Vega, C

INTERNATIONAL SEARCH REPORT

International Application No.

PLI/US 01/46753

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y | BURIONI R ET AL: "A new subtraction technique for molecular cloning of rare antiviral antibody specificities from phage display libraries." RESEARCH IN VIROLOGY, vol. 149, no. 5, 1998, pages 327-330, XP000863335 ISSN: 0923-2516 the whole document | 1-13 |
| Y | RUUD M.T. DE WILDT ET AL: "Antibody arrays for high-throughput screening of antibody-antigen interactions" NATURE BIOTECHNOLOGY, vol. 18, September 2000 (2000-09), pages 989-994, XP002162316 abstract page 990, right-hand column, paragraph 2 -page 992 | 1-13 |
| Y | WO 99 39210 A (HUMPHERY-SMITH) 5 August 1999 (1999-08-05) page 38, line 25 -page 39, line 7; claims 1-56 | 1-13 |
| Y | WO 97 10505 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 20 March 1997 (1997-03-20) page 44 -page 56; claims 4-7 | 1-13 |
| Y | MCCAFFERTY, J. ET AL: "Phage antibodies: filamentous phage displaying antibody variable domains" NATURE, vol. 348, 6 December 1990 (1990-12-06), pages 552-554, XP001019233 the whole document | 1-13 |

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 01/46753

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9939210 | A | 05-08-1999 | AU 740830 B2 | 15-11-2001 |
| | | | AU 2259799 A | 16-08-1999 |
| | | | WO 9939210 A1 | 05-08-1999 |
| | | | EP 1051624 A1 | 15-11-2000 |
| | | | JP 2002502038 T | 22-01-2002 |
| WO 9710505 | A | 20-03-1997 | AU 707484 B2 | 08-07-1999 |
| | | | AU 7073596 A | 01-04-1997 |
| | | | BR 9610580 A | 24-10-2000 |
| | | | CA 2231409 A1 | 20-03-1997 |
| | | | DE 852011 T1 | 11-10-2001 |
| | | | EP 0852011 A1 | 08-07-1998 |
| | | | JP 2000500005 T | 11-01-2000 |
| | | | NZ 318689 A | 25-02-1999 |
| | | | US 6290954 B1 | 18-09-2001 |
| | | | WO 9710505 A1 | 20-03-1997 |
| | | | US 5846533 A | 08-12-1998 |